替拉珠单抗治疗中重度银屑病52周疗效及生活质量影响的汇总分析
该汇总分析基于reSURFACE 1和2两项随机对照试验,纳入1156例中重度斑块状银屑病患者,评估替拉珠单抗100mg或200mg治疗至52周的疗效及生活质量。结果显示第28周PASI改善水平与DLQI 0/1相关,早期(第4-8周)可预测应答,且疗效和生活质量改善维持至52周。
要点
- 第8周可识别替拉珠单抗应答不佳者,第4周可预测PASI≥90应答。
- 第28周PASI改善水平越高,DLQI 0/1达成比例越高。
- 应答者继续治疗至52周,PASI改善和DLQI 0/1维持或改善。
核心结论
- 替拉珠单抗治疗中重度斑块状银屑病,第28周PASI改善水平与生活质量改善相关,早期可预测应答并维持至52周。
研究设计与样本
- 汇总reSURFACE 1和2两项随机对照试验,纳入1156例接受替拉珠单抗100mg或200mg治疗至28周的中重度斑块状银屑病患者。
主要发现
- 第28周,100mg组PASI<50、50-74、75-89、90-99和100的比例分别为8.3%、14.3%、23.8%、30.4%和23.1%;200mg组分别为4.0%、18.1%、19.6%、29.1%和29.3%。
- 第28周PASI<50的患者最早可在第8周识别,第28周PASI≥90的患者在第4周约获50% PASI改善。
- 第28周PASI>50且继续同剂量治疗至52周的患者,平均PASI改善维持或改善;两剂量结果相似。
- 第28周PASI分组越高,DLQI 0/1达成比例越高,且DLQI 0/1维持或改善至52周;但并非所有PASI 100患者达DLQI 0/1。
临床怎么用
- 临床可依据第4周PASI改善预测第28周PASI≥90应答,第8周识别可能应答不佳者。
- 治疗中应同时关注PASI改善和DLQI 0/1,以全面评估疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Two randomized controlled trials (reSURFACE 1 and 2) have demonstrated the effectiveness of tildrakizumab, a high-affinity, humanized, IgG1κ, anti-interleukin-23 monoclonal antibody, for treating moderate-to-severe plaque psoriasis in the first 28 weeks. OBJECTIVES: To examine the efficacy of tildrakizumab and its impact on quality of life (QoL) in patients with different levels of week-28 Psoriasis Area and Severity Index (PASI) improvement. METHODS: Patients treated with tildrakizumab 100 mg or 200 mg from baseline to week 28 were pooled from reSURFACE 1 and reSURFACE 2 and classified into five mutually exclusive week-28 PASI improvement groups for each dose: PASI 0-49, 50-74, 75-89, 90-99 and 100. Mean PASI improvement and Dermatology Life Quality Index (DLQI) 0/1 over time were examined for each group. RESULTS: Of 1156 patients, 575 were in the 100-mg and 578 in the 200-mg cohorts, respectively. At week 28, 8.3%, 14.3%, 23.8%, 30.4% and 23.1% in the 100-mg and 4.0%, 18.1%, 19.6%, 29.1% and 29.3% in the 200-mg cohort achieved PASI < 50, 50-74, 75-89, 90-99 and 100, respectively. Patients with PASI < 50 at week 28 could be identified as early as week 8, and those with week-28 PASI ≥ 90 had approximately 50% PASI improvement by week 4. Among patients achieving PASI > 50 at week 28 who continued the same dose of tildrakizumab to week 52, mean PASI improvement was maintained or improved over time. Similar results were observed for both doses. Higher proportions of patients achieved DLQI 0/1 in higher week-28 PASI groups, and DLQI 0/1 was maintained or improved to week 52. However, not all patients with PASI 100 had DLQI 0/1. CONCLUSION: Patients unlikely to respond to tildrakizumab could be identified by week 8, and those likely to achieve a PASI ≥ 90 response could be identified as early as week 4. Week-28 PASI improvement level correlated with QoL improvement.
引用
- Blauvelt A, Sofen H, Papp K, et al. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials. J Eur Acad Dermatol Venereol. 2019. PMID: 31407394. doi:10.1111/jdv.15862
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。